{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:24:51Z","timestamp":1786926291494,"version":"build-2736575974"},"reference-count":17,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4125,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2000,10]]},"abstract":"<jats:p>Anagrelide, a selective thrombocytopenic agent, is administered to treat a variety of hematologic disorders. Despite limited clinical experience with this drug, serious cardiovascular events, including congestive heart failure, have been reported. The proposed mechanism of cardiotoxicity is attributed to inhibition of phosphodiesterase, resulting in positive inotropic activity and vasodilation. A 48\u2010year\u2010old woman with polycythemia vera developed cardiotoxicity manifested by congestive heart failure and palpitations. It was suspected to be temporally related to titrating dosages of anagrelide.<\/jats:p>","DOI":"10.1592\/phco.20.15.1224.34591","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T07:23:33Z","timestamp":1086765813000},"page":"1224-1227","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anagrelide\u2010Induced Cardiomyopathy"],"prefix":"10.1002","volume":"20","author":[{"given":"Christopher W.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/ajhp\/55.19.1979","article-title":"Anagrelide, a selective thrombocytopenic agent","volume":"55","author":"Oertel MD","year":"1998","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_3_2","first-page":"1130","volume-title":"Hematology: basic principles and practice","author":"Hoffman R.","year":"2000"},{"key":"e_1_2_1_4_2","first-page":"1519","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"Petros WP","year":"1999"},{"key":"e_1_2_1_5_2","volume-title":"Agrylin (anagrelide) package insert","author":"Roberts Pharmaceutical Corp.","year":"1999"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90017-6"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90392-5"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252103"},{"key":"e_1_2_1_9_2","volume-title":"Pletal (cilostazol) package insert","author":"Otsuka America Pharmaceuticals.","year":"1999"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00114-9"},{"key":"e_1_2_1_11_2","volume-title":"Viagra (sildenafil) package insert","author":"Pfizer, Inc.","year":"1999"},{"key":"e_1_2_1_12_2","first-page":"315","article-title":"Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results","volume":"77","author":"Mazzucconi MG","year":"1992","journal-title":"Haematologica"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1999.tb01585.x"},{"issue":"1","key":"e_1_2_1_14_2","first-page":"51","article-title":"Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders","volume":"34","author":"Petitt RM","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_1_15_2","unstructured":"PetroneM. SilversteinM. PetittR. et al.The cardiovascular effects of anagrelide HCl in thrombocythemic subjects with and without prior medical history of cardiovascular disease [abstr]. Presented at the 96th annual meeting of the American Society for Clinical Pharmacology and Therapeutics San Diego March 1517 1995."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.3.557"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1994.9.291"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(80)90667-5"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.20.15.1224.34591","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.20.15.1224.34591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:19:52Z","timestamp":1761056392000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.20.15.1224.34591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["10.1592\/phco.20.15.1224.34591"],"URL":"https:\/\/doi.org\/10.1592\/phco.20.15.1224.34591","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,10]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}